IMVT News and Press, Immunovant Inc. From 09/26/23

2023-09-26 09:10:25 ET Investors seem to have lost their conviction in the stock market lately, as even brief attempts to rebound from declines have met with stiff resistance. For instance, Monday's trading session gave market participants some optimism about how the economy could weather d...

2023-09-26 08:21:55 ET Gainers: Soleno Therapeutics ( SLNO ) +154% . announces positive statistically significant top-line results from randomized withdrawal period of study C602 of DCCR for prader-willi syndrome. Immunovant ( IMVT ) +64% announces positive ini...

2023-09-26 08:00:34 ET (24/7 MARKET NEWS) – Immunovant, Inc. (NASDAQ:IMVT) reported, this morning, that subcutaneously administered doses of IMVT-1402 achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, in initial data from a...

2023-09-26 06:59:12 ET More on Immunovant Seeking Alpha’s Quant Rating on Immunovant Historical earnings data for Immunovant Financial information for Immunovant Immunovant Stock: With Anti-FcRn Validation Continuing, This Is A Must-Watch Immun...

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of d...

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Foll...

2023-08-10 10:42:57 ET Immunovant press release ( NASDAQ: IMVT ): Q2 GAAP EPS of -$0.57 misses by $0.13 . Immunovant’s cash and cash equivalents totaled $330.0 million, which is expected to fund operations into the second half of calendar year 2025. For fu...

Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose) Phase 2 proof-of-concept data for batoclimab in Graves’ disease (GD) expected in the fourth quarter of 2023 Glob...

2023-07-19 19:46:00 ET Shares of Immunovant ( NASDAQ: IMVT ) jumped 14% midday Monday amid the release of positive data for Argenx's ( ARGX ) drug Vyvgart Hytrulo, which is in the same drug class as Immunovant's drug candidate IMVT-1402. Argenx reported earlier Monday that a...

2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...